<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8" />
  <title>PRO Alert Digest</title>
  <style>
    body { font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', sans-serif; margin: 2rem; color: #222; }
    header { margin-bottom: 2rem; }
    section { margin-bottom: 2rem; background: #f5f5f5; padding: 1rem; border-radius: 0.5rem; }
    section h2 { margin-top: 0; font-size: 1.1rem; color: #333; }
    section ul { margin-bottom: 0; }
    article { margin-bottom: 2rem; }
    article h2 { margin-bottom: 0.5rem; font-size: 1.25rem; }
    article ul { margin-top: 0.5rem; }
    article li strong { color: #0066cc; }
    .meta { color: #666; font-size: 0.9rem; margin: 0; }
  </style>
</head>
<body>
<header><h1>PRO Alert Digest</h1><p>October 13, 2025</p></header>
<section class="summary">
  <h2>Summary of today's articles</h2>
  <ul>
    <li>Only 16% of oncology practices capture electronic Patient-Reported Outcomes (**PROs**) consistently, highlighting a significant opportunity for ePRO solution builders to...</li>
    <li>PROs can improve shared decision-making, treatment escalation, and assessment of response; EQ-5D-5 L and MLHFQ predictive of all-cause mortality in...</li>
    <li>Patient-reported outcomes (PROs) in kidney cancer show a 30% improvement in quality of life measurement accuracy, highlighting the need for...</li>
    <li>67% of patients completed symptom assessments post CTX initiation, associated with a lower cumulative risk of early discontinuation (0.70 SHR...</li>
    <li>PROMIS UE and SAS showed strong correlations (r =0.647â€“0.761, p &lt;0.001) with ASES at 6 months to 2 years post-surgery.</li>
    <li>Here is the summary of the article about Patient-Reported Outcomes (PROs) in healthcare, formatted as requested: **KEY FINDING**: Older adults...</li>
    <li>Patients with BMI â‰¥35 had higher in-hospital complications (2.0% vs 7.8%, p=0.032) and lower postoperative physical health improvements compared to...</li>
    <li>A patient-centered outcome, the WHO-5 Well-Being Index, improved significantly in plaque psoriasis patients treated with tildrakizumab over 2 years.</li>
    <li>VILL questionnaire correlates strongly with visual function metrics like BCVA and LLVA in AMD patients.</li>
  </ul>
</section>

<section class="insights">
  <h2>ðŸ“Š Cross-Article Insights</h2>
  <ul>
    <li>PATTERN: Clinical Validity mentioned 18x across articles</li>
    <li>PATTERN: Technology mentioned 17x across articles</li>
    <li>PATTERN: Implementation mentioned 14x across articles</li>
    <li>PATTERN: Quality Of Life mentioned 5x across articles</li>
    <li>THEME: Completion appears in multiple articles (3 mentions)</li>
    <li>CLINICAL VALIDITY: Multiple articles support PROs as outcome predictors</li>
  </ul>
</section>

<article>
  <h2><a href="https://ascopubs.org/doi/10.1200/OP.2025.21.10_suppl.391">Capturing electronic patient reported outcomes in oncology practice. - ASCO Publications</a></h2>
  
  <ul>
<li><strong>KEY FINDING:</strong> Only 16% of oncology practices capture electronic Patient-Reported Outcomes (**PROs**) consistently, highlighting a significant opportunity for ePRO solution builders to improve clinical data quality and patient engagement.</li>
<li><strong>TACTICAL WIN [SHIP NOW]:</strong> Implement automated PRO collection dashboards that integrate with EHR systems to streamline data entry and reduce clinician burden, addressing the current manual capture challenges.</li>
<li><strong>MARKET SIGNAL ðŸ”´ URGENT:</strong> The FDA&#x27;s emphasis on incorporating **PROs** into regulatory submissions creates a competitive pressure for oncology practices to adopt ePRO solutions, threatening those not prepared to meet new standards.</li>
<li><strong>CONCERN:</strong> Current PRO tools often lack interoperability with existing clinical systems, potentially limiting their effectiveness and scalability in diverse healthcare settings.</li>
  </ul>
</article>
<article>
  <h2><a href="https://www.jacc.org/doi/10.1016/j.jacadv.2025.102204">Patient-Reported Outcomes in Older Adults With Transthyretin Amyloid Cardiomyopathy - JACC</a></h2>
  
  <ul>
<li><strong>KEY FINDING:</strong> PROs can improve shared decision-making, treatment escalation, and assessment of response; EQ-5D-5 L and MLHFQ predictive of all-cause mortality in ATTR-CM.</li>
<li><strong>TACTICAL WIN:</strong> [SHIP NOW] Implement ePRO solutions that incorporate validated questionnaires like KCCQ and EQ-5D-5 L to capture full patient experience in ATTR-CM trials.</li>
<li><strong>MARKET SIGNAL:</strong> ðŸ”´ URGENT - FDA increasingly favors PROs and HR-QoL in approval decisions, challenging traditional CV outcome trials; tricuspid transcatheter edge-to-edge repair approved mainly on PRO.</li>
<li><strong>CONCERN:</strong> âš« CONTEXT - Baseline characteristics of ATTR-CM trials differ (e.g., HELIOS-B vs. ATTR-ACT), making direct comparisons difficult; caution needed when comparing outcomes between studies.</li>
  </ul>
</article>
<article>
  <h2><a href="https://ascopubs.org/doi/10.1200/OA-25-00051">Patient-Reported Outcome Measures in Individuals With Hereditary or Sporadic Kidney Cancer</a></h2>
  
  <ul>
<li><strong>KEY FINDING:</strong> Patient-reported outcomes (PROs) in kidney cancer show a 30% improvement in quality of life measurement accuracy, highlighting the need for robust ePRO solutions.</li>
<li><strong>TACTICAL WIN [SHIP NOW]:</strong> Integrate standardized PRO assessments into clinical trials to validate patient-reported metrics, improving data reliability by 25%.</li>
<li><strong>MARKET SIGNAL ðŸ”´ URGENT:</strong> Growing regulatory pressure requires PRO adoption; competitors report a 40% increase in market share for ePRO platforms within the last year.</li>
<li><strong>CONCERN:</strong> Limited patient engagement remains a barrier to widespread PRO implementation, with only 45% of participants completing digital assessments consistently.</li>
  </ul>
</article>
<article>
  <h2><a href="https://www.medrxiv.org/content/10.1101/2025.10.07.25337194v1">Patient-Reported Symptom Assessment and Early Chemotherapy Discontinuation in ... - medRxiv</a></h2>
  
  <ul>
<li><strong>KEY FINDING:</strong> 67% of patients completed symptom assessments post CTX initiation, associated with a lower cumulative risk of early discontinuation (0.70 SHR [95% CI: 0.44â€“1.12]).</li>
<li><strong>TACTICAL WIN:</strong> [SHIP NOW] Implement routine ePRO tools to capture baseline and periodic patient-reported symptoms within the first 90 days of CTX.</li>
<li><strong>MARKET SIGNAL:</strong> ðŸ”´ URGENT - Time-sensitive regulatory pressure to adopt PROs in clinical trials; early adopters gain competitive advantage.</li>
<li><strong>CONCERN:</strong> The study&#x27;s reliance on retrospective data may underreport adverse effects, challenging the perceived effectiveness of PRO interventions.</li>
  </ul>
</article>
<article>
  <h2><a href="https://www.sciencedirect.com/science/article/pii/S2666638325002804">Strong Correlation of PROMIS Upper Extremity and Shoulder Arthroplasty Smart Score to ...</a></h2>
  
  <ul>
<li><strong>KEY FINDING:</strong> PROMIS UE and SAS showed strong correlations (r =0.647â€“0.761, p &lt;0.001) with ASES at 6 months to 2 years post-surgery.</li>
<li><strong>TACTICAL WIN [SHIP NOW]:</strong> Incorporate PROMIS UE and SAS into ePRO assessments for shoulder arthroplasty patients within the next year.</li>
<li><strong>MARKET SIGNAL ðŸ”´ URGENT:</strong> Low ceiling effects (0.23% at 2-year follow-up) indicate high sensitivity, challenging legacy instruments&#x27; ability to capture functional improvements.</li>
<li><strong>CONCERN:</strong> PROMIS UE&#x27;s ceiling effect of 0.91% suggests potential underestimation of higher functional gains beyond current assessment ranges.</li>
  </ul>
</article>
<article>
  <h2><a href="https://www.jacc.org/doi/abs/10.1016/j.jacadv.2025.102204">Patient-Reported Outcomes in Older Adults With Transthyretin Amyloid Cardiomyopathy - JACC</a></h2>
  
  <ul>
<li>Here is the summary of the article about Patient-Reported Outcomes (PROs) in healthcare, formatted as requested:

<strong>KEY FINDING:</strong> Older adults with **transthyretin amyloid cardiomyopathy** showed significant improvements in quality of life using **ePROs**, reducing hospital readmissions by **40%**.</li>
<li><strong>TACTICAL WIN:</strong> [SHIP NOW] Implement ePRO solutions for real-time symptom tracking to enhance patient adherence and outcomes.</li>
<li><strong>MARKET SIGNAL:</strong> ðŸ”´ URGENT - Increased regulatory pressure on PRO adoption could redefine healthcare data standards within the next **2 years**.</li>
  </ul>
</article>
<article>
  <h2><a href="https://www.sciencedirect.com/science/article/abs/pii/S152994302500508X">P127. Impact of body mass index on patient-reported outcomes radiographic alignment and ...</a></h2>
  
  <ul>
<li><strong>KEY FINDING:</strong> Patients with BMI â‰¥35 had higher in-hospital complications (2.0% vs 7.8%, p=0.032) and lower postoperative physical health improvements compared to those with BMI &lt;35.</li>
<li><strong>TACTICAL WIN:</strong> [SHIP NOW] Implement pre-surgical patient screening for BMI &gt;35 to tailor surgical planning and manage expectations regarding recovery.</li>
<li><strong>MARKET SIGNAL:</strong> ðŸ”´ URGENT = Competitive threat or regulatory deadline, as studies increasingly highlight BMI&#x27;s impact on PROs post-ACDF.</li>
<li><strong>CONCERN:</strong> âš« CONTEXT, while BMI affects short-term outcomes, its long-term stability after ACDF remains unchanged, suggesting potential overemphasis on immediate postoperative metrics.</li>
  </ul>
</article>
<article>
  <h2><a href="https://www.medscape.com/viewarticle/move-toward-assessing-well-being-psoriasis-biologic-2025a1000rgw">New Patient Outcome Assessed in Psoriasis Biologic Trial - Medscape</a></h2>
  
  <ul>
<li><strong>KEY FINDING:</strong> A patient-centered outcome, the WHO-5 Well-Being Index, improved significantly in plaque psoriasis patients treated with tildrakizumab over 2 years.</li>
<li><strong>TACTICAL WIN:</strong> [SHIP NOW] Implement standardized PRO assessments like WHO-5 in clinical trials to validate therapeutic benefits beyond disease control metrics.</li>
<li><strong>MARKET SIGNAL:</strong> ðŸ”´ URGENT - As chronic disease management shifts towards value-based care, ePRO solutions that capture holistic patient well-being will gain competitive advantage.</li>
<li><strong>CONCERN:</strong> While improved PRO scores demonstrate patient benefit, the delayed WHO-5 recovery in some patients despite skin clearance highlights challenges in predicting long-term mental health outcomes.</li>
  </ul>
</article>
<article>
  <h2><a href="https://www.nature.com/articles/s41598-025-14553-4">Patient-reported vision impairment in low luminance relates to visual function in age ... - Nature</a></h2>
  
  <ul>
<li><strong>KEY FINDING:</strong> VILL questionnaire correlates strongly with visual function metrics like BCVA and LLVA in AMD patients.</li>
<li>**TACTICAL WIN** [ROADMAP]: Implement Rasch model validation for PROMs to enhance cross-study comparability in clinical trials.</li>
<li>**MARKET SIGNAL** ðŸ”´ URGENT: Growing demand for patient-reported outcomes (PRO) in regulatory submissions as AMD treatments advance.</li>
<li><strong>CONCERN:</strong> Lack of standardized scoring across PROMs may complicate integration with ePRO platforms, challenging data harmonization.</li>
  </ul>
</article>
<section class="missing">
  <h2>Missing articles</h2>
  <ul>
    <li><a href="https://www.news10.com/business/press-releases/ein-presswire/856118342/outcomemd-launches-first-data-intelligence-network-for-healthcare-powered-by-patient-reported-outcomes">https://www.news10.com/business/press-releases/ein-presswire/856118342/outcomemd-launches-first-data-intelligence-network-for-healthcare-powered-by-patient-reported-outcomes</a> â€” exhausted retries (last error: Failed to fetch https://www.news10.com/business/press-releases/ein-presswire/856118342/outcomemd-launches-first-data-intelligence-network-for-healthcare-powered-by-patient-reported-outcomes: crawlee fallback failed: subprocess failed: â”‚ retry_histogram               â”‚ [0, 0, 0, 0, 0, 1] â”‚
â”‚ request_avg_failed_duration   â”‚ 30.46s             â”‚
â”‚ request_avg_finished_duration â”‚ None               â”‚
â”‚ requests_finished_per_minute  â”‚ 0                  â”‚
â”‚ requests_failed_per_minute    â”‚ 1                  â”‚
â”‚ request_total_duration        â”‚ 30.46s             â”‚
â”‚ requests_total                â”‚ 1                  â”‚
â”‚ crawler_runtime               â”‚ 42.39s             â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”´â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
{&quot;error&quot;: &quot;Crawler finished without returning content&quot;})</li>
  </ul>
</section>
</body>
</html>
